rss
Postgrad Med J 2009;85:196-201 doi:10.1136/pgmj.2008.073577
  • Review

Nicotine: does it have a role in the treatment of skin disease?

  1. J R Ingram
  1. Dr J R Ingram, Department of Dermatology, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK; johningram{at}hotmail.co.uk
  • Received 27 July 2008
  • Accepted 21 December 2008

Abstract

Epidemiological evidence suggests that, although smoking is detrimental in some skin diseases, it is of benefit in others such as pemphigus and Behcet disease. Evidence that nicotine is of therapeutic value in selected skin diseases is limited to case reports. There has been renewed interest in nicotinic acetylcholine receptor agonists, such as nicotine, after the discovery of a “nicotinic anti-inflammatory pathway”. Nicotinic acetylcholine receptors exist in abundance in human skin, but it is unknown whether they exert an anti-inflammatory effect. Randomised controlled trials of nicotine preparations in those skin conditions that occur less often in smokers are necessary to establish the value of nicotine, if any, in the treatment of skin disease.

Footnotes

  • Competing interests: JRI received financial support from SLA Pharma for work involving nicotine enemas in ulcerative colitis.

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.